资源描述：
《艾塞那肽和沙格列丁治疗2型糖尿病的对比分析》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、艾塞那肽和沙格列丁治疗2型糖尿病的对比分析(青岛市第八人民医院内分泌科山东青岛266100)【摘要】目的：探讨艾塞那肽与沙格列汀在2型糖尿病的血糖、糖化血红蛋白控制等方面的作用，并进行比较。方法：收治120例口服二甲双胍控制不佳的2型糖尿病患者，随机分为A组60例，在二甲双胍基础上联合应用艾塞那肽皮下注射治疗；B组60例，在二甲双胍基础上口服沙格列汀治疗。两组患者治疗4个月后，比较治疗前后的血糖、血压、体重等指标。结果：两组患者治疗4个月后，空腹血糖、餐后2小时血糖、糖化血红蛋白值、舒张压、收缩压等指标，均比治疗前有明显改善(P<0.
2、05)；但在腰围和体重方面，A组比治疗前有明显改善(P<0.05),B组则无显著改善效果(P>0.05)o两组间上述指标比较，除舒张压外，A组其他指标的改善程度均显著优于B组(P<0.05)。A组的糖化血红蛋白达标率明显高于B组(P<0.05)。结论：艾塞那肽与沙格列汀均可有效降低2型糖尿病患者的HbAlc水平、有效控制患者血糖，改善其血压,但艾塞那肽的效果更为明显，且在控制体重和腰围方面有显著效果，值得在临床推广应用。【关键词】2型糖尿病；艾塞那肽；沙格列汀；糖化血红蛋白【中图分类号】R587【文献标识码】A【文章
3、编号】1004-6194(2015)02-0196-02ComparativeanalysisofcurativeeffectofByettaandSaxagliptinintreatingType2diabetesWangHaiyan,WuQian.DepartmentofEndocrinology,QingDaoEighthPeople’sHospital,Qingdao,Shandong,266100.【Abstract】Objective:Tocomparetheeffectofbyettaandsaxagliptini
4、ncontrolingbloodglucoseandglycosylatedhemoglobinoftype2diabetespatients.Methods:120type2diabetespatientswithpoorcontrolwhooraltakemetforminwererandomlydividedintogroupA(n=60)treatedwithmetformincombinedsubcutaneousinjectionofbyettaandgroupB(n=60)withmetformincombinedoralta
5、kingsaxagliptin.After4months,bloodglucose,bloodpressure,weightandotherindicatorsoftwogroupswerecomparedbetweenbeforeandaftertreatment.Results:After4months,fastingbloodglucose,2hourspostprandialbloodglucose,glycosylatedhemoglobin,diastolicbloodpressure,systolicbloodpressure
6、andotherindicatorsweresignificantlyimprovedthanbeforetreatment(P<0.05).Asforwaistandbodyweight,groupAsignificantlyimprovedthanbeforetreatment(P<0.05),groupBhasnosignificantimprovement(P>0.05).TheaboveindicatorsofgroupAweresignificantlybetterthanthatofBgroup(P<0
7、.05),exceptfordiastolicbloodpressure.CompliancerateofglycosylatedhemoglobiningroupAsignificantlyhigherthangroupB(P<0.05).Conclusions:ByettaandsaxagliptincaneffectivelyreducethelevelofHbAlcandbloodglucoseinpatientswithtype2diabetesandimprovetheirbloodpressure.Theeffectof
8、byettawasmoreobvious,andithadasignificanteffectoncontrollingweightandwaist.Itisworthyofcl
